Sign In
Buy OFIX
Orthofix International N.V Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $0.120 |
| EPS actual | $0.200 |
| EPS Surprise | 66.67% |
| Revenue estimate | 199.987M |
| Revenue actual | 205.634M |
| Revenue Surprise | 2.82% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.0400 |
| EPS actual | $0.130 |
| EPS Surprise | 225.00% |
| Revenue estimate | 201.149M |
| Revenue actual | 203.121M |
| Revenue Surprise | 0.98% |
| Release date | May 06, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0800 |
| EPS Surprise | 52.94% |
| Revenue estimate | 204.237M |
| Revenue actual | 193.646M |
| Revenue Surprise | -5.19% |
| Release date | Feb 25, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0200 |
| EPS Surprise | -66.67% |
| Revenue estimate | 199.701M |
| Revenue actual | 215.657M |
| Revenue Surprise | 7.99% |
Last 4 Quarters for Orthofix International N.V
Below you can see how OFIX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $17.51 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0200 |
| EPS surprise | -66.67% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $18.49 |
| Feb 20, 2025 | $18.10 |
| Feb 21, 2025 | $17.95 |
| Feb 24, 2025 | $18.15 |
| Feb 25, 2025 | $17.51 |
| Feb 26, 2025 | $17.26 |
| Feb 27, 2025 | $17.21 |
| Feb 28, 2025 | $17.38 |
| Mar 03, 2025 | $16.98 |
| 4 days before | -5.30% |
| 4 days after | -3.03% |
| On release day | -1.43% |
| Change in period | -8.17% |
| Release date | May 06, 2025 |
| Price on release | $12.06 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0800 |
| EPS surprise | 52.94% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $13.91 |
| May 01, 2025 | $13.55 |
| May 02, 2025 | $13.79 |
| May 05, 2025 | $13.54 |
| May 06, 2025 | $12.06 |
| May 07, 2025 | $12.02 |
| May 08, 2025 | $12.31 |
| May 09, 2025 | $12.11 |
| May 12, 2025 | $12.43 |
| 4 days before | -13.30% |
| 4 days after | 3.07% |
| On release day | -0.332% |
| Change in period | -10.64% |
| Release date | Aug 05, 2025 |
| Price on release | $12.31 |
| EPS estimate | $0.0400 |
| EPS actual | $0.130 |
| EPS surprise | 225.00% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $11.36 |
| Jul 31, 2025 | $11.04 |
| Aug 01, 2025 | $10.77 |
| Aug 04, 2025 | $10.85 |
| Aug 05, 2025 | $12.31 |
| Aug 06, 2025 | $12.54 |
| Aug 07, 2025 | $12.70 |
| Aug 08, 2025 | $12.51 |
| Aug 11, 2025 | $12.94 |
| 4 days before | 8.36% |
| 4 days after | 5.12% |
| On release day | 1.87% |
| Change in period | 13.91% |
| Release date | Nov 04, 2025 |
| Price on release | $14.87 |
| EPS estimate | $0.120 |
| EPS actual | $0.200 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $15.32 |
| Oct 30, 2025 | $15.47 |
| Oct 31, 2025 | $15.44 |
| Nov 03, 2025 | $16.06 |
| Nov 04, 2025 | $14.87 |
| Nov 05, 2025 | $14.97 |
| Nov 06, 2025 | $14.68 |
| Nov 07, 2025 | $14.96 |
| Nov 10, 2025 | $15.03 |
| 4 days before | -2.94% |
| 4 days after | 1.08% |
| On release day | 0.672% |
| Change in period | -1.89% |
Orthofix International N.V Earnings Call Transcript Summary of Q3 2025
Orthofix reported a solid Q3 2025 with pro forma net sales of $203.4M, up 6% year-over-year, led by strength in U.S. Spine Fixation and U.S. Orthopedics. Key growth drivers include adoption of the 7D FLASH navigation system, distributor channel optimization, and new product introductions (notably the limited market release of the VIRATA spinal fixation system, TrueLok Elevate, and FITBONE products). Q3 marked the seventh consecutive quarter of adjusted EBITDA margin expansion, with pro forma adjusted EBITDA of $24.6M (12.1% margin) and positive free cash flow of $2.5M; pro forma gross margin improved to 72.1%. Management narrowed full-year pro forma net sales guidance to $810M–$814M (midpoint $812M) and raised the bottom end of full-year pro forma non-GAAP adjusted EBITDA guidance to $84M–$86M (midpoint $85M), while reiterating full-year positive free cash flow (excluding M6-related restructuring). Strategic priorities remain: deepen 7D adoption/commercial execution, improve gross margins through operational initiatives, and maintain disciplined capital allocation to drive margin expansion and free cash flow. Management highlighted VIRATA's upcoming full commercial launch (expected H2 2026 start, fuller impact in 2027) and continued distributor transitions as catalysts for share gains and acceleration toward long-range CAGR targets.
